Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Matinas Biopharma Hl (MTNB)

Matinas Biopharma Hl (MTNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 945,576
  • Shares Outstanding, K 250,816
  • Annual Sales, $ 1,100 K
  • Annual Income, $ -22,940 K
  • 60-Month Beta 1.65
  • Price/Sales 16.11
  • Price/Cash Flow N/A
  • Price/Book 0.94
Trade MTNB with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.03
  • Growth Rate Est. (year over year) +3,330,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.28 +12.50%
on 09/06/24
5.70 -35.32%
on 08/21/24
-2.61 (-41.43%)
since 08/20/24
3-Month
3.28 +12.50%
on 09/06/24
9.60 -61.56%
on 07/16/24
-4.12 (-52.72%)
since 06/20/24
52-Week
3.28 +12.50%
on 09/06/24
44.50 -91.71%
on 10/11/23
-3.14 (-45.97%)
since 09/20/23

Most Recent Stories

More News
Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022 FDA Provides Flexibility...

MTNB : 3.69 (-2.12%)
Matinas BioPharma to Participate in the BTIG Biotechnology Conference

BEDMINSTER, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving...

MTNB : 3.69 (-2.12%)
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022

BEDMINSTER, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical...

MTNB : 3.69 (-2.12%)
Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 for the Treatment of Cryptococcosis

BEDMINSTER, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving...

MTNB : 3.69 (-2.12%)
Matinas BioPharma to Present at the LD Micro Invitational XII Conference

BEDMINSTER, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving...

MTNB : 3.69 (-2.12%)
Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights

– Announced an exclusive research collaboration with BioNTech focused on the combination of mRNA and Matinas’ proprietary LNC platform technology – ...

MTNB : 3.69 (-2.12%)
Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial and Operational Results on May 12, 2022

BEDMINSTER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused...

MTNB : 3.69 (-2.12%)
Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference

BEDMINSTER, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining...

MTNB : 3.69 (-2.12%)
Matinas BioPharma to Present at the Needham Virtual Healthcare Conference

BEDMINSTER, N.J., April 06, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on...

MTNB : 3.69 (-2.12%)
Matinas BioPharma to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

BEDMINSTER, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on...

MTNB : 3.69 (-2.12%)

Business Summary

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines,...

See More

Key Turning Points

3rd Resistance Point 3.99
2nd Resistance Point 3.90
1st Resistance Point 3.80
Last Price 3.69
1st Support Level 3.61
2nd Support Level 3.52
3rd Support Level 3.42

See More

52-Week High 44.50
Fibonacci 61.8% 28.75
Fibonacci 50% 23.89
Fibonacci 38.2% 19.03
Last Price 3.69
52-Week Low 3.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar